New Two-Drug attack on breast cancer before surgery
NCT ID NCT07317778
Summary
This study is testing whether adding two new drugs (adebrelimab and SHR-A1811) to standard chemotherapy is more effective than chemo alone for patients with a specific type of early-stage breast cancer before surgery. The main goal is to see if the new combinations lead more patients to have no detectable cancer in their breast and lymph nodes after treatment. About 249 participants will be randomly assigned to receive one of three treatment plans over about 6 months, followed by surgery and monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, 100021, China
Conditions
Explore the condition pages connected to this study.